Literature DB >> 28265849

Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?

Barbara Neerinckx1, Rik J Lories2.   

Abstract

PURPOSE OF THE REVIEW: Progressive ankylosis is a feared consequence of long-standing axial spondyloarthritis. We aim to critically review current insights into the effect of therapy, the molecular pathways involved in this process, and to present a model explaining the sequence of events. RECENT
FINDINGS: Long-term follow-up data suggest that successful control of inflammation may slow down radiographic progression of disease in axial spondyloarthritis. Structural effects of new therapies such as interleukin-17 targeting need to be further studied. Bone loss and architectural changes could act as driver for the tissue remodeling process trying to maintain spinal stability in the presence of inflammation. Despite some progress, the nature and mechanisms of new bone formation in axial spondyloarthritis still remain incompletely understood. However, long-term control of inflammation appears critical to avoid progressive disability due to structural damage.

Entities:  

Keywords:  Ankylosing spondylitis; Ankylosis; Axial spondyloarthritis; Bone; Spondyloarthritis; Structural disease progression

Mesh:

Substances:

Year:  2017        PMID: 28265849     DOI: 10.1007/s11926-017-0639-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

1.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors:  Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

2.  Proinflammatory T cells and IL-17 stimulate osteoblast differentiation.

Authors:  Michiel Croes; F Cumhur Öner; Danihel van Neerven; Ekrem Sabir; Moyo C Kruyt; Taco J Blokhuis; Wouter J A Dhert; Jacqueline Alblas
Journal:  Bone       Date:  2016-01-11       Impact factor: 4.398

3.  Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis.

Authors:  Walter P Maksymowych; Stephanie Wichuk; Praveena Chiowchanwisawakit; Robert G Lambert; Susanne J Pedersen
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

Review 4.  Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

Authors:  Johanna Callhoff; Joachim Sieper; Anja Weiß; Angela Zink; Joachim Listing
Journal:  Ann Rheum Dis       Date:  2014-04-09       Impact factor: 19.103

5.  Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis.

Authors:  Gisela Ruiz-Heiland; Angelika Horn; Pawel Zerr; Willy Hofstetter; Wolfgang Baum; Michael Stock; Jörg H Distler; Falk Nimmerjahn; Georg Schett; Jochen Zwerina
Journal:  Ann Rheum Dis       Date:  2012-01-10       Impact factor: 19.103

6.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

Authors:  Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler
Journal:  Arthritis Rheum       Date:  2013-10

7.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

8.  Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis.

Authors:  M-C Park; Y-B Park; S-K Lee
Journal:  Scand J Rheumatol       Date:  2008 May-Jun       Impact factor: 3.641

Review 9.  Pathophysiology of new bone formation and ankylosis in spondyloarthritis.

Authors:  Rik J U Lories; Georg Schett
Journal:  Rheum Dis Clin North Am       Date:  2012-09-07       Impact factor: 2.670

10.  Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Elena E Solomou; Anastasia Tsanaktsi; Konstadina Bounia; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Arthritis Rheum       Date:  2010-01
View more
  6 in total

1.  Tenascin-C, a biomarker of disease activity in early ankylosing spondylitis.

Authors:  Latika Gupta; Shruti Bhattacharya; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

2.  Serum CCL11 level is associated with radiographic spinal damage in patients with ankylosing spondylitis.

Authors:  Dong Hyun Sohn; Hoim Jeong; Jong Seong Roh; Han-Na Lee; Eunsung Kim; Jung Hee Koh; Seung-Geun Lee
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

3.  No evidence for a direct role of HLA-B27 in pathological bone formation in axial SpA.

Authors:  Barbara Neerinckx; Simon Kollnberger; Jacqueline Shaw; Rik Lories
Journal:  RMD Open       Date:  2017-06-29

4.  Low bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis.

Authors:  Hyoung Rae Kim; Yeon Sik Hong; Sung-Hwan Park; Ji Hyeon Ju; Kwi Young Kang
Journal:  Arthritis Res Ther       Date:  2018-10-16       Impact factor: 5.156

Review 5.  To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis.

Authors:  Fabio Massimo Perrotta; Rik Lories; Ennio Lubrano
Journal:  RMD Open       Date:  2021-02

6.  Enhanced BMP-2/BMP-4 ratio in patients with peripheral spondyloarthritis and in cytokine- and stretch-stimulated mouse chondrocytes.

Authors:  Anne Briolay; Alaeddine El Jamal; Paul Arnolfo; Benoît Le Goff; Frédéric Blanchard; David Magne; Carole Bougault
Journal:  Arthritis Res Ther       Date:  2020-10-12       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.